Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 5
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Gandjour, Afschin 2015. Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions. Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 15, Issue. 1, p. 43.


    Schiffmann, Raphael 2010. Agalsidase treatment for Fabry disease: Uses and rivalries. Genetics in Medicine, Vol. 12, Issue. 11, p. 684.


    Adarkwah, Charles Christian and Gandjour, Afschin 2011. Cost–effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease. Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 11, Issue. 2, p. 215.


    Huang, Yunyu Zhou, Qiyun Haaijer-Ruskamp, Flora M and Postma, Maarten J 2014. Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review. BMC Nephrology, Vol. 15, Issue. 1,


    Gandjour, Afschin Tschulena, Ulrich Steppan, Sonja and Gatti, Emanuele 2015. A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease. Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 15, Issue. 2, p. 341.


    ×
  • International Journal of Technology Assessment in Health Care, Volume 26, Issue 1
  • January 2010, pp. 62-70

Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany

  • Charles Christian Adarkwah (a1) and Afschin Gandjour (a2)
  • DOI: http://dx.doi.org/10.1017/S0266462309990584
  • Published online: 08 January 2010
Abstract

Objectives: Type 2 diabetes is the main cause of end-stage renal disease in Europe and the United States. Angiotensin-converting enzyme (ACE) inhibitors slow down the progression of renal disease and, therefore, provide a renal-protective effect. The aim of this study was to assess the most cost-effective time to start an ACE inhibitor (or an angiotensin II receptor blocker in the event of cough) in patients with type 2 diabetes in Germany.

Methods: Three strategies were compared: treating all patients at the time of diagnosing type 2 diabetes, screening for microalbuminuria, and screening for macroalbuminuria. A lifetime Markov decision model with simulated 50-year-old patients with newly diagnosed diabetes mellitus was developed using published data on costs and health outcomes and simulating the progression of renal disease. A statutory health insurance perspective was adopted.

Results: In the base-case analysis, the treat-all strategy is associated with the lowest costs and highest benefit and, therefore, dominates screening both for macroalbuminuria and microalbuminuria. A multivariate sensitivity analysis shows that the probability of savings is 89 percent.

Conclusions: Patients with type 2 diabetes should receive an ACE inhibitor immediately after diagnosis if they do not have contraindications. The potential for cost savings would be even larger if the prevention of cardiovascular events were considered.

Copyright
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.J Ahmad , MA Siddiqui , H Ahmad . Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20:15761581.

2.T Arnesen , M Trommald . Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy. 2004;9:4350.

3.AH Barnett , SC Bain , P Bouter , et al; for the Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:19521961.

4.AG Bertoni , JS Krop , GF Anderson , Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25:471475.

5.H Bleichrodt , M Johannesson . Standard gamble, time trade-off and rating scale: Experimental results on the ranking properties of QALYs. J Health Econ. 1997;16:155175.

6.S Braun , A Prenzler , T Mittendorf , Appraisal of resource use in the German health-care system from the perspective of the statutory health insurance [in German]. Gesundheitswesen. 2009;71:1923.

7.AH Briggs , AE Ades , MJ Price . Probabilistic sensitivity analysis for decision trees with multiple branches: Use of the Dirichlet distribution in a Bayesian framework. Med Decis Making. 2003;23:341350.

8.GC Brown , MM Brown , S Sharma , Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14:1824.

10.JP Casas , W Chua , S Loukogeorgakis , Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet. 2005;366:20262033.

12.WD Comper , TM Osicka , G Jerums . High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis. 2003;41:336342.

13.DJ Cook , GH Guyatt . Interpreting, integrating, and individualizing evidence about the prevention of diabetic nephropathy. Ann Intern Med. 1999;131:707708.

14.P Dolan , C Gudex , P Kind , Valuing health states: A comparison of methods. J Health Econ. 1996;15:209231.

16.A Gandjour , F Kleinschmit , KW Lauterbach ; INTERCARE International Investigators. European comparison of costs and quality in the prevention of secondary complications in Type 2 diabetes mellitus (2000–2001). Diabet Med. 2002;19:594601.

19.L Golan , JD Birkmeyer , HG Welch . The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999;131:660667.

21.Guideline of the American Diabetes Association (ADA). Nephropathy in Diabetes. Diabetes Care. 2004;27 (Suppl):79S83S.

23.Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253259.

26. BL Kasiske , RS Kalil , JZ Ma , Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med. 1993;118:129138.

28. I Koester , L von Ferber , P Ihle , The cost burden of diabetes mellitus: The evidence from Germany—the CoDiM Study. Diabetologia. 2006;49:14981504.

29.RJ Koopman , AG III Mainous , VA Diaz , Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med. 2005;3:6063.

31.EJ Lewis , LG Hunsicker , RP Bain , The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:14561462.

32.EJ Lewis , LG Hunsicker , WR Clarke , Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851860.

33.DB Matchar , DC McCrory , LA Orlando , Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:1629.

37.LK Niskanen , I Penttila , M Parviainen , Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care. 1996;19:486493.

38. HH Parving , H Lehnert , J Brochner-Mortensen , The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870878.

39.AB Rosen , BH Hamel , MC Weinstein , Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143:8999.

50.The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:17871792.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Type Description Title
UNKNOWN
Supplementary Materials

Adarkwah et al. supplementary materials
Table 1 and Figure 1

 Unknown (100 KB)
100 KB